Financials data is unavailable for this security.
View more
Year on year Boston Scientific Corp grew revenues 12.29% from 12.68bn to 14.24bn while net income improved 128.22% from 698.00m to 1.59bn.
Gross margin | 69.08% |
---|---|
Net profit margin | 11.98% |
Operating margin | 17.51% |
Return on assets | 5.16% |
---|---|
Return on equity | 9.48% |
Return on investment | 6.07% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Boston Scientific Corp fell by 71.00m. However, the company earned 2.50bn from its operations for a Cash Flow Margin of 17.58%. In addition the company generated 5.00m cash from financing while 2.57bn was spent on investing.
Cash flow per share | 2.06 |
---|---|
Price/Cash flow per share | 39.83 |
Book value per share | 13.85 |
---|---|
Tangible book value per share | 0.3786 |
More ▼
Balance sheet in USDView more
Current ratio | 1.61 |
---|---|
Quick ratio | 1.14 |
Total debt/total equity | 0.5189 |
---|---|
Total debt/total capital | 0.339 |
More ▼
Growth rates in USD
SmartText is unavailable
EPS growth(5 years) | -1.29 |
---|---|
EPS (TTM) vs TTM 1 year ago | 108.14 |